Trial · NCT07194044
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
NCT07194044, Phase 1, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes. Trials, record NCT07194044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07194044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- NCT number
- NCT07194044
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 15 participants, estimated
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Conditions
- Metastatic Ewing Sarcoma
- Interventions
- Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Actinomycin, Irinotecan, Cabozantinib, Topotecan, Temozolomide, Etoposide, Liposomal doxorubicin
- First posted
- 2025-09-26
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility and Safety - Consolidation | 16 months | The treatment will be considered feasible if 70% of Ewing sarcoma patients make it through consolidation. |
| Primary | Feasibility and Safety - Maintenance | 16 months | The treatment will be considered feasible if 50% of Ewing sarcoma patients make it through 6 cycles of maintenance. |
| Secondary | Event-Free Survival | 3 years | EFS is defined as time from treatment initiation to event which includes (1) recurrence, (2) secondary malignancy, and (3) death due to any cause. |
| Secondary | Off Treatment Event Free Survival | 3 years | otEFS is defined as time from treatment initiation to event 66 which includes (1) any recurrence (local or regional, or distant) that leads to coming off protocol therapy and (2) death due to any cause. |
| Secondary | Overall Survival | 3 years | The time to event endpoint of overall survival is defined as the duration of time from diagnosis to death or last follow-up timepoint, where event would be death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07194044
GET https://conductscience.org/api/trials/v1/NCT07194044/registered